{
    "clinical_study": {
        "@rank": "33301", 
        "arm_group": [
            {
                "arm_group_label": "Reference", 
                "arm_group_type": "Active Comparator", 
                "description": "nicotine transdernal patch with the existing polyisobutylene adhesive"
            }, 
            {
                "arm_group_label": "Treatement", 
                "arm_group_type": "Active Comparator", 
                "description": "nicotine transdernal patch with the alternate polyisobutylene adhesive"
            }
        ], 
        "brief_summary": {
            "textblock": "Bioequivalence study to confirm that a NTS with a polyisobutylene (PIB) adhesive from an\n      alternative supplier delivers the same nicotine blood profile as that of the currently\n      approved NTS with a polyisobutylene adhesive from the current supplier."
        }, 
        "brief_title": "A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers", 
        "completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "condition": "Smoking", 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  BMI 19-27 kg/m2\n\n          -  smokes >10 cigarettes per day for preceeding 6 months\n\n        Exclusion Criteria:\n\n          -  inability to stop smoking during study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01702519", 
            "org_study_id": "RH01418"
        }, 
        "intervention": {
            "arm_group_label": [
                "Treatement", 
                "Reference"
            ], 
            "description": "nicotine transdermal patch", 
            "intervention_name": "nicotine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Nicotine", 
                "Nicotine polacrilex"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lincoln", 
                    "country": "United States", 
                    "state": "Nebraska", 
                    "zip": "68502"
                }, 
                "name": "Celerion NEBRASKA"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Area under the plasma concentration time curve from zero and extrapolated to the time of last quantifiable sample was determined by plasma concentration time profile of nicotine.", 
                "measure": "Area under the curve from time 0 to the last quantifiable sample, AUC(0-t)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples were drawn at several time points: immediately pre-dose, and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 20, 24, 25, 26, 28, and 32 hours after wearing the patch."
            }, 
            {
                "description": "Maximum plasma nicotine concentration was determined from plasma concentration time profiles.", 
                "measure": "Maximum Measured Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples drawn at various time points including: immediately pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 20, 24, 25, 26, 28, and 32 hours."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01702519"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Area under the plasma nicotine concentration time curve from zero extrapolated to infinity was determined", 
                "measure": "Area under the concentration time curve between zero and infinity, AUC (0-inf)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples drawn at various time points including: immediately pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 20, 24, 25, 26, 28, and 32 hours."
            }, 
            {
                "description": "Tmax was determined from plasma concentration time profile.", 
                "measure": "Time to Maximum Plasma Concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples drawn at various time points including: immediately pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 20, 24, 25, 26, 28, and 32 hours."
            }, 
            {
                "description": "The elimination half-life of drug was determined.", 
                "measure": "Plasma half-life (t1/2),", 
                "safety_issue": "No", 
                "time_frame": "Blood samples were drawn at several time points: immediately pre-dose, and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 20, 24, 25, 26, 28, and 32 hours after wearing the patch."
            }, 
            {
                "description": "Elimination rate constant for nicotine was calculated.", 
                "measure": "Rate of elimination (Kel)", 
                "safety_issue": "No", 
                "time_frame": "Blood samples were drawn at several time points: immediately pre-dose, and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 20, 24, 25, 26, 28, and 32 hours after wearing the patch."
            }
        ], 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}